Antiatherogenic activity of silybin in Wistar rats: an experimental study
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20212782Keywords:
Dyslipidemia, Atherosclerosis, Coronary heart disease, SilybinAbstract
Background: Dyslipidemia is the major contributor to an increased risk of atherosclerosis. Furthermore, Atherosclerosis presently comprises one of the essential contributors to a global epidemic of cardiovascular disease and turn out to be the leading cause of death and disability worldwide. Natural antioxidants have been shown to be effective in reducing lipid profiles and mitigate peroxidative modification of lipoproteins and atherosclerosis. The aim of the study was to explore the antiatherogenic effect of silybin through its antioxidant mechanism in Wister rats fed on hypercholesterolemic diet.
Methods: Male Wistar rats of 150-200 g were used for this study. Hypercholesterolemia in rats was induced by administration of high cholesterol diet. The Wister rats were divided into four groups, each with eight rats. After 60 days blood samples were drawn by retro-orbital puncture for biochemical analysis. The animals were sacrificed by cervical dislocation and liver and aorta were dissected out and processed for histopathological study and biochemical analyses.
Results: In the histopathological study high cholesterol fed Wister rats showed fatty degeneration of hepatocytes with leucocytic infiltration of sinusoids. The level of TBARS was significantly increased in high cholesterol diet fed rats (p<0.05). Silybin at both doses [300 mg/kg (1593.00±81.08) and 600 mg/kg (1596.00±28.81)] reduced the plasma TBARS significantly (p<0.05). The antioxidant enzyme levels were also reduced significantly in high cholesterol diet fed rats (p<0.05).
Conclusions: The study suggests a conclusive evidence of silybin has antiatherogenic action. Its safety profile, availability and low cost are an added advantage to the presently available pharmacological therapy. Hence, silybin can be considered in conjunction with other available dyslipidemic medication in the market.
References
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021.
Soehnlein O, Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov. 2021;1-22.
Krishnan MN. Coronary heart disease and risk factors in India - on the brink of an epidemic?. Indian Heart J. 2012;64(4):364-7.
Gomar F, Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016;4(13):256.
Narayanamurthy U, Anandhi M, Manimekalai K. Effect of lutein on lipid profile in hypercholesterolemic rats. Int J Basic Clin Pharmacol.2018;7(5):859-65.
Lee YT, Laxton V, Lin HY, Chan YWF, Smith S, To TLO, et al. Animal models of atherosclerosis. Biomed Rep. 2017;6(3):259-66.
Zuo S, Wang G, Han Q, Xiao H, Santos H, Avelar RD, et al. The effects of tocotrienol supplementation on lipid profile: A meta-analysis of randomized controlled trials. Complement Ther Med. 2020;52:102450.
Incalza MA, Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018;100:1-19.
Astrup A, Magkos F, Bier DM, Brenna JT, Oliveira OMC, Hill JO, et al. Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;76(7):844-57.
Narayanamurthy U, Anandhi M, Manimekalai K. Effect of lutein on lipid profile in hypercholesterolemic rats. Int J Basic Clin Pharmacol. 2018;7(5):859.
Subramani C, Rajakkannu A, Rathinam A, Gaidhani S, Raju I, Kartar SDV. Anti-atherosclerotic activity of root bark of Premna integrifolia Linn. in high fat diet induced atherosclerosis model rats. J Pharm Anal. 2017;7(2):123-8.
Pęczek P, Lesniewski M, Mazurek T, Szarpak L, Filipiak KJ, Gąsecka A. Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia. Life. 2021;11(6):466.
Ospina JC, Wu Z, Geng Y, Moshage H. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy. Antioxidants. 2021;10(2):174.
Niimi M, Chen Y, Yan H, Wang Y, Koike T, Fan J. Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development. Applied Sci. 2020;10(23):8681.
Valentova K, Purchartova K, Rydlova L, Roubalova L, Biedermann D, Petraskova L, et al. Sulfated Metabolites of Flavonolignans and 2,3-Dehydroflavonolignans: Preparation and Properties. Int J Mol Sci. 2018;19(8):2349.
Kordkheyli V, Goudarzi K, Laskokalayeh M, Zarpou S, Tarsi A. The protective effects of silymarin on ischemia-reperfusion injuries: A mechanistic review. Iran J Basic Med Sci. 2019;22(9):968-76.
Taleb A, Ahmad KA, Ihsan AU, Qu J, Lin N, Hezam K, Koju N, et al. Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases. Biomed Pharmacother. 2018;102:689-98.
Miyazaki T, Miyazaki A. Impact of Dysfunctional Protein Catabolism on Macrophage Cholesterol Handling. Curr Med Chem. 2019;26(9):1631-43.
